{"transactions":[{"id":732922,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:09:11.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":307521,"source":{"system":"sec-edgar","filing":"0001808098-26-000003","document":"wk-form4_1781813348.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000180809826000003/wk-form4_1781813348.xml","form_type":"4"}},{"id":738716,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:33.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":6.21,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-271168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000119312526271168/ownership.xml","form_type":"4"}},{"id":738715,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T20:30:33.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":194167,"source":{"system":"sec-edgar","filing":"0001193125-26-271168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000119312526271168/ownership.xml","form_type":"4"}},{"id":1106991,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:15:49.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":250421,"source":{"system":"sec-edgar","filing":"0001725160-25-000133","document":"wk-form4_1750277742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516025000133/wk-form4_1750277742.xml","form_type":"4"}},{"id":1106990,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T20:10:34.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":6.18,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-25-087890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017025087890/ownership.xml","form_type":"4"}},{"id":1106989,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:10:34.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":179167,"source":{"system":"sec-edgar","filing":"0000950170-25-087890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017025087890/ownership.xml","form_type":"4"}},{"id":1141287,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants (right to buy)","published_at":"2025-05-20T21:43:51.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 16, 2025, the Reporting Person purchased 20,000 shares of the Issuer's common stock and a warrant to purchase 5,000 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 16, 2025, the Reporting Person purchased 20,000 shares of the Issuer's common stock and a warrant to purchase 5,000 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering."}],"balance_after":5000,"derivative":{"exercise_price":4.9,"exercise_date":"2025-05-16","expiration_date":"2030-05-16","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-25-075412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017025075412/ownership.xml","form_type":"4"}},{"id":1141286,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-20T21:43:51.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":4.9,"value":98000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 16, 2025, the Reporting Person purchased 20,000 shares of the Issuer's common stock and a warrant to purchase 5,000 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering."}],"balance_after":166167,"source":{"system":"sec-edgar","filing":"0000950170-25-075412","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017025075412/ownership.xml","form_type":"4"}},{"id":1471418,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T20:05:23.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":14500,"derivative":{"exercise_price":6.93,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0000950170-24-076707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017024076707/ownership.xml","form_type":"4"}},{"id":1471417,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-24T20:05:23.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":146167,"source":{"system":"sec-edgar","filing":"0000950170-24-076707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017024076707/ownership.xml","form_type":"4"}},{"id":1472603,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T21:07:33.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":48429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":192818,"source":{"system":"sec-edgar","filing":"0001725160-24-000141","document":"wk-form4_1719004045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516024000141/wk-form4_1719004045.xml","form_type":"4"}},{"id":1745110,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T22:24:19.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":17000,"price":9.879,"value":167943.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.70 to $9.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":144389,"source":{"system":"sec-edgar","filing":"0001725160-23-000201","document":"wk-form4_1699914237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516023000201/wk-form4_1699914237.xml","form_type":"4"}},{"id":1746287,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T22:02:28.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":7.3,"value":73000.0,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $7.22 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0000950170-23-062214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023062214/ownership.xml","form_type":"4"}},{"id":1746286,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T22:02:28.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":7.3,"value":73000.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $7.22 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0000950170-23-062214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023062214/ownership.xml","form_type":"4"}},{"id":1746285,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T22:02:28.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":9601,"price":7.3,"value":70087.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $7.22 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":135667,"source":{"system":"sec-edgar","filing":"0000950170-23-062214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023062214/ownership.xml","form_type":"4"}},{"id":1746284,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T22:02:28.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":47000,"price":7.17,"value":336990.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $6.50 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0000950170-23-062214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023062214/ownership.xml","form_type":"4"}},{"id":1746283,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T22:02:28.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":47000,"price":7.17,"value":336990.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $6.50 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0000950170-23-062214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023062214/ownership.xml","form_type":"4"}},{"id":1746282,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T22:02:28.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":76000,"price":7.17,"value":544920.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $6.50 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":126066,"source":{"system":"sec-edgar","filing":"0000950170-23-062214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023062214/ownership.xml","form_type":"4"}},{"id":1764701,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-05T23:56:36.000Z","date":"2023-10-04","kind":"purchase","planned":false,"acquired":true,"shares":6566,"price":8.6068,"value":56512.2488,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.52 to $8.66, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":50066,"source":{"system":"sec-edgar","filing":"0000950170-23-052244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023052244/ownership.xml","form_type":"4"}},{"id":1764700,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-05T23:56:36.000Z","date":"2023-10-03","kind":"purchase","planned":false,"acquired":true,"shares":13500,"price":8.2713,"value":111662.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.00 to $8.51, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":43500,"source":{"system":"sec-edgar","filing":"0000950170-23-052244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000095017023052244/ownership.xml","form_type":"4"}},{"id":1853467,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:04:20.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":19059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":127389,"source":{"system":"sec-edgar","filing":"0001725160-23-000146","document":"wk-form4_1686949452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516023000146/wk-form4_1686949452.xml","form_type":"4"}},{"id":1861417,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:56:26.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":12.83,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000899243-23-015206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924323015206/doc4.xml","form_type":"4"}},{"id":2059480,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T22:55:37.000Z","date":"2023-01-06","kind":"purchase","acquired":true,"shares":904,"price":10.51,"value":9501.04,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0000899243-23-001324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924323001324/doc4.xml","form_type":"4"}},{"id":2059479,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T22:55:37.000Z","date":"2023-01-06","kind":"purchase","acquired":true,"shares":700,"price":10.5,"value":7350.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0000899243-23-001324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924323001324/doc4.xml","form_type":"4"}},{"id":2059478,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T22:55:37.000Z","date":"2023-01-05","kind":"purchase","acquired":true,"shares":96,"price":10,"value":960.0,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":17096,"source":{"system":"sec-edgar","filing":"0000899243-23-001324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924323001324/doc4.xml","form_type":"4"}},{"id":2059477,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T22:55:37.000Z","date":"2023-01-05","kind":"purchase","acquired":true,"shares":300,"price":10,"value":3000.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":17300,"source":{"system":"sec-edgar","filing":"0000899243-23-001324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924323001324/doc4.xml","form_type":"4"}},{"id":2074643,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-31T00:01:18.000Z","date":"2022-12-28","kind":"purchase","acquired":true,"shares":2000,"price":9.75,"value":19500.0,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0000899243-22-039594","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322039594/doc4.xml","form_type":"4"}},{"id":2074642,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-31T00:01:18.000Z","date":"2022-12-28","kind":"purchase","acquired":true,"shares":2000,"price":9.75,"value":19500.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0000899243-22-039594","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322039594/doc4.xml","form_type":"4"}},{"id":2085767,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-15T23:15:36.000Z","date":"2022-12-01","kind":"purchase","acquired":true,"shares":5000,"price":12.37,"value":61850.0,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000899243-22-038695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322038695/doc4.xml","form_type":"4"}},{"id":2085766,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-15T23:15:36.000Z","date":"2022-12-01","kind":"purchase","acquired":true,"shares":5000,"price":12.37,"value":61850.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000899243-22-038695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322038695/doc4.xml","form_type":"4"}},{"id":2229003,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T21:07:59.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":13.72,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000899243-22-023128","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322023128/doc4.xml","form_type":"4"}},{"id":2233421,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-15T01:29:20.000Z","date":"2022-06-13","kind":"purchase","acquired":true,"shares":20000,"price":13.99,"value":279800.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000899243-22-022456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322022456/doc4.xml","form_type":"4"}},{"id":2233420,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-15T01:29:20.000Z","date":"2022-06-13","kind":"purchase","acquired":true,"shares":7000,"price":13.99,"value":97930.0,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-22-022456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322022456/doc4.xml","form_type":"4"}},{"id":2233419,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-15T01:29:20.000Z","date":"2022-06-13","kind":"purchase","acquired":true,"shares":7000,"price":13.99,"value":97930.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-22-022456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322022456/doc4.xml","form_type":"4"}},{"id":2233418,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-15T01:29:20.000Z","date":"2022-06-10","kind":"purchase","acquired":true,"shares":10000,"price":15.04,"value":150400.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-22-022456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322022456/doc4.xml","form_type":"4"}},{"id":2233417,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-15T01:29:20.000Z","date":"2022-06-10","kind":"purchase","acquired":true,"shares":3000,"price":15.04,"value":45120.0,"ownership":{"direct":false,"nature":"By NEJ12 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-22-022456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322022456/doc4.xml","form_type":"4"}},{"id":2233416,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-15T01:29:20.000Z","date":"2022-06-10","kind":"purchase","acquired":true,"shares":3000,"price":15.04,"value":45120.0,"ownership":{"direct":false,"nature":"By NEJ09 IRREVOCABLE TRUST"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-22-022456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924322022456/doc4.xml","form_type":"4"}},{"id":2236867,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T20:22:09.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":24871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 8, 2023 or (b) the next occurring annual meeting of the Company's stockholders, subject to the Reporting Person's continued service on the Board of Directors through such vesting date."}],"balance_after":108330,"source":{"system":"sec-edgar","filing":"0001725160-22-000121","document":"wf-form4_165489251364998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516022000121/wf-form4_165489251364998.xml","form_type":"4"}},{"id":2468809,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-17T22:57:19.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":52.25,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001725160-21-000242","document":"wf-form4a_163978182697479.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000242/wf-form4a_163978182697479.xml","form_type":"4/A","original_submission_date":"2021-06-08"}},{"id":2468808,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T22:57:19.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed to correct the number of RSUs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 7,500 RSUs on June 4, 2021, to vest on the first to occur of (a) June 4, 2022 or (b) the next occurring annual meeting of the Company's stockholders."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Due to the error described above, the Reporting Person's Form 4 filed on October 4, 2021 incorrectly reported that the number of shares held by the Reporting Person was 80,959 shares of Common Stock."}],"balance_after":96355,"source":{"system":"sec-edgar","filing":"0001725160-21-000242","document":"wf-form4a_163978182697479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000242/wf-form4a_163978182697479.xml","form_type":"4/A","original_submission_date":"2021-06-08"}},{"id":2529945,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2021-11-02T20:11:32.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":139672,"ownership":{"direct":false,"nature":"By Velocity Capital Management LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Velosity Capital Management LLC is an entity that the reporting person is the sole member of."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":139672},"source":{"system":"sec-edgar","filing":"0000899243-21-042361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924321042361/doc4.xml","form_type":"4"}},{"id":2529944,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T20:11:32.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":139672,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Velocity Capital Management"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Velosity Capital Management LLC is an entity that the reporting person is the sole member of."}],"balance_after":139672,"source":{"system":"sec-edgar","filing":"0000899243-21-042361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924321042361/doc4.xml","form_type":"4"}},{"id":2532269,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-29T23:33:19.000Z","date":"2021-10-28","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as follows: These shares will vest in full on October 28, 2022."}],"balance_after":24000,"derivative":{"exercise_price":14,"expiration_date":"2031-10-27","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-21-042095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924321042095/doc4.xml","form_type":"4"}},{"id":2553339,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T01:15:10.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":100,"price":67.2,"value":6720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."}],"balance_after":80959,"source":{"system":"sec-edgar","filing":"0001725160-21-000197","document":"wf-form4_163339649177277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000197/wf-form4_163339649177277.xml","form_type":"4"}},{"id":2553338,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T01:15:10.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":7904,"price":66.579,"value":526240.416,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.16 to $67.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":81059,"source":{"system":"sec-edgar","filing":"0001725160-21-000197","document":"wf-form4_163339649177277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000197/wf-form4_163339649177277.xml","form_type":"4"}},{"id":2553337,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T01:15:10.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":4892,"price":65.9501,"value":322627.8892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.16 to $66.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":88963,"source":{"system":"sec-edgar","filing":"0001725160-21-000197","document":"wf-form4_163339649177277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000197/wf-form4_163339649177277.xml","form_type":"4"}},{"id":2678414,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-08T21:26:57.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":52.25,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001725160-21-000142","document":"wf-form4_162318757634162.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000142/wf-form4_162318757634162.xml","form_type":"4"}},{"id":2678413,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-08T21:26:57.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 4, 2022 or (b) the next occurring annual meeting of the Company's stockholders, subject to the Reporting Person's continued service on the Board of Directors through such vesting date."}],"balance_after":93855,"source":{"system":"sec-edgar","filing":"0001725160-21-000142","document":"wf-form4_162318757634162.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000142/wf-form4_162318757634162.xml","form_type":"4"}},{"id":2759616,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T23:54:11.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":12897,"price":43.5001,"value":561020.7897,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."}],"balance_after":88855,"source":{"system":"sec-edgar","filing":"0001725160-21-000079","document":"wf-form4_161766675973088.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516021000079/wf-form4_161766675973088.xml","form_type":"4"}},{"id":2959508,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T22:57:29.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":2825,"price":52.72,"value":148934.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.39 to $53.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":101752,"source":{"system":"sec-edgar","filing":"0001725160-20-000052","document":"wf-form4_160703623563271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516020000052/wf-form4_160703623563271.xml","form_type":"4"}},{"id":2959507,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T22:57:29.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":4603,"price":51.61,"value":237560.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.32 to $52.26. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":104577,"source":{"system":"sec-edgar","filing":"0001725160-20-000052","document":"wf-form4_160703623563271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516020000052/wf-form4_160703623563271.xml","form_type":"4"}},{"id":2959506,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T22:57:29.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":3868,"price":50.82,"value":196571.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.32 to $51.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":109180,"source":{"system":"sec-edgar","filing":"0001725160-20-000052","document":"wf-form4_160703623563271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516020000052/wf-form4_160703623563271.xml","form_type":"4"}},{"id":2959505,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T22:57:29.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":1600,"price":49.8,"value":79680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.30 to $50.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":113048,"source":{"system":"sec-edgar","filing":"0001725160-20-000052","document":"wf-form4_160703623563271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516020000052/wf-form4_160703623563271.xml","form_type":"4"}},{"id":2959504,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T22:57:29.000Z","date":"2020-04-07","kind":"purchase","acquired":true,"shares":4000,"price":18,"value":72000.0,"ownership":{"direct":true},"balance_after":114648,"source":{"system":"sec-edgar","filing":"0001725160-20-000052","document":"wf-form4_160703623563271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516020000052/wf-form4_160703623563271.xml","form_type":"4"}},{"id":3179353,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-09T20:31:31.000Z","date":"2020-04-07","kind":"grant","acquired":true,"shares":51587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest over a twenty-four month period following the grant date."}],"balance_after":110648,"source":{"system":"sec-edgar","filing":"0000899243-20-010605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000089924320010605/doc4.xml","form_type":"4"}}]}